$Torrid(CURV.US)$rose more than 25% after hours Thursday after the plus-sized clothing maker beat analyst estimates for Q4 revenues and overall results. CURV soared 26% to trade at $6.15 shortly before 4:45 p.m. ET after the company reported a $0.04 loss per share – narrower than the $0.07 analysts had reportedly expected. The company also recorded $293.5 million of quarterly revenues vs. the $276....
The declining ROCE and revenue despite increased capital deployment is a concerning trend for Torrid Holdings. While the stock has performed well over the past year, these underlying trends do not bode well for its long-term performance.
MBIA ($MBIA(MBI.US)$) stock is rocketing more than 58% after declaring a special cash dividend. Exicure ($Exicure(XCUR.US)$) shares are soaring over 55% alongside heavy pre-market trading. FLJ ($楓林居(FLJ.US)$) stock is surging close to 45% with strong early morning trading. Torrid ($Torrid(CURV.US)$) shares are gaining more than 16% after releasing its Q3 earnings report. Meta Materials ($Meta Materials(MMAT.US)$) stock is increasing ...
Torrid Holdings's stock seems overpriced compared to its peers and might face a price drop. With the negative growth outlook, it might be a good time for shareholders to de-risk. It may not be an ideal time for potential investors to enter due to overvaluation and negative future outlook.
Abercrombie and Fitch beat analyst expectations with fastest revenue growth. Contrarily, Torrid reported slowest growth and weak full-year guidance, causing a fall in stock price.
The increasing demand for GLP-1 weight-loss medications indicates that in the next ten years, a significant number of Americans may lose hundreds of millions of pounds collectively. This shift in weight could cause a redistribution of trillions of dollars. Last week,$諾和諾德(NVO.US)$presented evidence of a speeding trend when it announced that the primary component of Ozempic and Wegovy, ...
Declining revenue trend and disparity with industry growth might drag Torrid Holdings' P/S ratios and share price. Possible overpay by investors due to gloomy revenue outlook coupled with potential disappointments from persistent negative growth and diminishing returns.
Torrid股票討論區
🩳 Interest.
$Yield10 Bioscience(YTEN.US)$$Lytus Technologies Holdings(LYT.US)$$Avalo Therapeutics(AVTX.US)$$Gamida Cell(GMDA.US)$$Torrid(CURV.US)$$祁連國際(QLI.US)$
📊⚡️📊
Get Some!! 🚨⚡️🚨⚡️🚨
📊⚡️📊
專欄Torrid Holdings Gains More Than 25% After Hours After Plus-Sized Clothier Reports Narrower Q4 Loss
CURV soared 26% to trade at $6.15 shortly before 4:45 p.m. ET after the company reported a $0.04 loss per share – narrower than the $0.07 analysts had reportedly expected.
The company also recorded $293.5 million of quarterly revenues vs. the $276....
Biggest Pre-Market Stock Movers: 10 Top Gainers
Exicure ( $Exicure(XCUR.US)$ ) shares are soaring over 55% alongside heavy pre-market trading.
FLJ ( $楓林居(FLJ.US)$ ) stock is surging close to 45% with strong early morning trading.
Torrid ( $Torrid(CURV.US)$ ) shares are gaining more than 16% after releasing its Q3 earnings report.
Meta Materials ( $Meta Materials(MMAT.US)$ ) stock is increasing ...
專欄Novo Nordisk Sets New Record High: Analyzing the Market Effects of Popular GLP-1 Weight Loss Drugs
Last week, $諾和諾德(NVO.US)$ presented evidence of a speeding trend when it announced that the primary component of Ozempic and Wegovy, ...
暫無評論